Chronic renal failure future or investigational therapies

Emerging Therapies

Primary, secondary, and tertiary prevention of CKD is increasingly possible because of genetic diagnoses.
A recent study involving a small molecule Inaxaplin reverses the toxic gain-of-function effect of APOL1 high-risk variants, in patients with two APOL1 variants and biopsy-proven FSGS.
A mouse model showed that gene transfer of Pkd1 trans gene lead to re expression of polycystic 1 protein thereby markedly delayed cyst development, retarded cyst progression, and postponed kidney failure in Pkd